Archives

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

B Consumers can now order NEREUS™ directly at nereus.us WASHINGTON, May 4, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™… Login to continue reading Login…

Read MoreVanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors’ Microbiome Evaluation at ESCMID Global 2026

B DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activity Neutropenic CD-1 mice were infected intramuscularly with… Login to continue reading Login…

Read MoreAcurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors’ Microbiome Evaluation at ESCMID Global 2026